Indeed, it has been reported that primitive CML cells remain insensitive to IM despite the inhibition of BCR-ABL activity, and therapies that biochemically target this activity will not entirely eliminate CML stem cells, which may persist in patients despite prolonged treatment [6,7]. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.